Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE

Abstract Detection of autoantibodies in systemic lupus erythematosus (SLE) plays an important role in timely diagnosis and earlier treatment of SLE. In this study, we used a SmD1 polypeptide-based ELISA to determine anti-SmD1 antibody in 269 SLE, including100 naïve (had not been treated with steroid...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chaojun Hu, Mengtao Li, Jian Liu, Junyan Qian, Dong Xu, Shulan Zhang, Ping Li, Jiulang Zhao, Xinping Tian, Xiaofeng Zeng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3559e4807f944e0a86038e3c176b28fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3559e4807f944e0a86038e3c176b28fa
record_format	dspace
spelling	oai:doaj.org-article:3559e4807f944e0a86038e3c176b28fa2021-12-02T12:30:44ZAnti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE10.1038/s41598-017-08099-32045-2322https://doaj.org/article/3559e4807f944e0a86038e3c176b28fa2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-08099-3https://doaj.org/toc/2045-2322Abstract Detection of autoantibodies in systemic lupus erythematosus (SLE) plays an important role in timely diagnosis and earlier treatment of SLE. In this study, we used a SmD1 polypeptide-based ELISA to determine anti-SmD1 antibody in 269 SLE, including100 naïve (had not been treated with steroids or immunosuppressants at study inception) SLE patients and 169 non-naive SLE patients; 233 controls with other rheumatic diseases (RDC) (70 RA, 40 AS, 73SSc, and 50 SS), and 110 healthy controls (HC) group. The positive rate of anti-SmD1 among all SLE patients was 60.97%, higher than that in the RDC group (13.30%, P = 0.000) or the HC group (9.09%, P = 0.000). The positive rate of anti-SmD1 in non-naive SLE patients was higher than that for anti-dsDNA antibodies (44.97%, P = 0.03). Positivity for anti-SmD1 only was found in 14.00% of naive SLE patients and 16.00% of non-naive SLE patients. In naive SLE patients, the serum concentration of anti-SmD1 was lower after treatment than before treatment (P = 0.039). Active SLE patients positive for anti-SmD1 were more likely to have malar rash, rash, nonscarring alopecia, PAH and hypocomplementemia. High positivity for anti-SmD1 only in patients with SLE indicated the importance and necessity of detection of anti-SmD1 in patients with SLE.Chaojun HuMengtao LiJian LiuJunyan QianDong XuShulan ZhangPing LiJiulang ZhaoXinping TianXiaofeng ZengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chaojun Hu Mengtao Li Jian Liu Junyan Qian Dong Xu Shulan Zhang Ping Li Jiulang Zhao Xinping Tian Xiaofeng Zeng Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE
description	Abstract Detection of autoantibodies in systemic lupus erythematosus (SLE) plays an important role in timely diagnosis and earlier treatment of SLE. In this study, we used a SmD1 polypeptide-based ELISA to determine anti-SmD1 antibody in 269 SLE, including100 naïve (had not been treated with steroids or immunosuppressants at study inception) SLE patients and 169 non-naive SLE patients; 233 controls with other rheumatic diseases (RDC) (70 RA, 40 AS, 73SSc, and 50 SS), and 110 healthy controls (HC) group. The positive rate of anti-SmD1 among all SLE patients was 60.97%, higher than that in the RDC group (13.30%, P = 0.000) or the HC group (9.09%, P = 0.000). The positive rate of anti-SmD1 in non-naive SLE patients was higher than that for anti-dsDNA antibodies (44.97%, P = 0.03). Positivity for anti-SmD1 only was found in 14.00% of naive SLE patients and 16.00% of non-naive SLE patients. In naive SLE patients, the serum concentration of anti-SmD1 was lower after treatment than before treatment (P = 0.039). Active SLE patients positive for anti-SmD1 were more likely to have malar rash, rash, nonscarring alopecia, PAH and hypocomplementemia. High positivity for anti-SmD1 only in patients with SLE indicated the importance and necessity of detection of anti-SmD1 in patients with SLE.
format	article
author	Chaojun Hu Mengtao Li Jian Liu Junyan Qian Dong Xu Shulan Zhang Ping Li Jiulang Zhao Xinping Tian Xiaofeng Zeng
author_facet	Chaojun Hu Mengtao Li Jian Liu Junyan Qian Dong Xu Shulan Zhang Ping Li Jiulang Zhao Xinping Tian Xiaofeng Zeng
author_sort	Chaojun Hu
title	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE
title_short	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE
title_full	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE
title_fullStr	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE
title_full_unstemmed	Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE
title_sort	anti-smd1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in chinese patients with active sle
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/3559e4807f944e0a86038e3c176b28fa
work_keys_str_mv	AT chaojunhu antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT mengtaoli antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT jianliu antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT junyanqian antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT dongxu antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT shulanzhang antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT pingli antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT jiulangzhao antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT xinpingtian antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle AT xiaofengzeng antismd1antibodiesareassociatedwithrenaldisorderseizuresandpulmonaryarterialhypertensioninchinesepatientswithactivesle
_version_	1718394326250160128

Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE

Ejemplares similares